Opendata, web and dolomites


Discovering a novel allergen immunotherapy in house dust mite allergy tolerance research

Total Cost €


EC-Contrib. €






Project "MATCH" data sheet

The following table provides information about the project.


Organization address
address: DE BOELELAAN 1117
postcode: 1081 HV

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 150˙000.00


 Project objective

The advances in medical sciences and biopharmaceutical development during the last decennia have been overwhelming. While the scientific and clinical insight in numerous diseases have significantly increased, the curative treatment to most diseases is still not in reach. The most common diseases such as cancer and chronic diseases are still challenging scientists. Therefore, during our ERC Advanced project the main goal was to develop a vaccine to cure cancer using targeted immunotherapy. We used dendritic cells (DCs) as potentiator to improve anti-tumor T cell activity. However, we discovered that many tumors display a high content of sialic acids which actively suppress DCs function and induce tolerance to tumor associated antigens. This unexpected serendipity finding that sialylation of tumor associated antigens induced tolerance to the body’s immune response opens a window of opportunity to use sialylation (modification with sialic acid) to induce tolerance in allergies, such as house dust mite allergy (HDM). In the ERC PoC project (MATCH) I will couple HDM major allergens to specific sialic acid using a linker molecule to induce immune tolerance towards effector T cells in inflammation processes during HDM allergy. The results will lead to validation of the technology developed during the ERC Advanced project and PoC that sialylation induces tolerance when used with HDM allergens. When PoC is reached, the MATCH technology will represent a new allergen immunotherapy in a vaccine technology for HDM allergy with shorter treatment protocols, better efficacy and reduced side effects can be developed. The future potential of this technology may be extended to other allergies and/or autoimmune diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MATCH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MATCH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CELPRED (2020)

Circuit elements of the cortical circuit for predictive processing

Read More  

TORYD (2020)

TOpological many-body states with ultracold RYDberg atoms

Read More  

SiMS (2019)

Simulated Majorana states

Read More